Chemical Structure (A9942f9c 5929 4b9b Aa27 64f7f9b164e3 01)
Chemical structure of Alendronate Sodium showing its molecular arrangement and bonding.*
Alendronate Sodium
Product Images NDC 66116-428
10 FDA label images from Medvantx, Inc. · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 66116-428). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Medvantx, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (A9942f9c 5929 4b9b Aa27 64f7f9b164e3 02)
A line graph comparing cumulative incidence percentages over 36 months between placebo and Alendronate Sodium. The graph tracks time in months on the x-axis and cumulative incidence percentage on the y-axis, showing lower incidence for Alendronate Sodium compared to placebo throughout the period.*
Figure 2 (A9942f9c 5929 4b9b Aa27 64f7f9b164e3 03)
A bar graph comparing the mean percentage increase in Bone Mineral Density (BMD) relative to placebo with standard error across three bone sites: Lumbar Spine, Femoral Neck, and Trochanter, for two groups labeled U.S. and Multinational. The U.S. group consistently shows slightly higher BMD increase in all three areas compared to the Multinational group.*
Figure 3 (top) (A9942f9c 5929 4b9b Aa27 64f7f9b164e3 04)
A line graph titled 'U.S. Study' showing the mean percentage change in bone mineral density (BMD) from baseline over 36 months. It compares Alendronate 10 mg and placebo groups, with BMD increasing steadily for Alendronate and remaining near baseline for placebo.*
Figure 3 (bottom) (A9942f9c 5929 4b9b Aa27 64f7f9b164e3 05)
A line graph titled 'Multinational Study' showing the mean percentage change in Bone Mineral Density (BMD) from baseline over 36 months. The graph compares Alendronate 10 mg and placebo groups, with Alendronate showing a steady increase in BMD over time, while the placebo group remains near baseline. The y-axis represents BMD percentage change, and the x-axis represents time in months.*
Figure 4 (top) (A9942f9c 5929 4b9b Aa27 64f7f9b164e3 06)
A bar chart titled 'Change in BMD From Baseline 2 Year Study' comparing bone mineral density (BMD) changes between Alendronate 5 mg/day and placebo groups. Four anatomical sites are shown: Lumbar Spine, Femoral Neck, Trochanter, and Total Body, with BMD changes represented as mean percentage change ± SE. Alendronate shows positive BMD changes at all sites, while placebo shows decreases.*
Figure 4 (bottom) (A9942f9c 5929 4b9b Aa27 64f7f9b164e3 07)
A bar chart showing the mean percentage change in Bone Mineral Density (BMD) from baseline over a 3-year study. It compares Alendronate 5 mg/day versus placebo at four skeletal sites: Lumbar Spine, Femoral Neck, Trochanter, and Total Body, illustrating positive BMD changes with Alendronate and declines with placebo at these sites.*
Figure 5 (A9942f9c 5929 4b9b Aa27 64f7f9b164e3 08)
A bar graph comparing mean percentage increase in bone mineral density (BMD) relative to placebo plus standard error between U.S. and Multinational groups for the lumbar spine, femoral neck, and trochanter regions.*
Figure 6 (A9942f9c 5929 4b9b Aa27 64f7f9b164e3 09)
A line graph showing serum alkaline phosphatase mean percent change from baseline over 6 months for four groups: Placebo, Etidronate 400 mg/day, Alendronate 40 mg/day in a multinational study, and Alendronate 40 mg/day in a U.S. study. The y-axis represents mean percent change with standard error, and the x-axis shows time in months. The graph compares the biochemical effects of these treatments over time.*
Alendronate Sodium 70mg Tablets #4 (A9942f9c 5929 4b9b Aa27 64f7f9b164e3 10)
Label for Alendronate Sodium Tablets USP 70 mg, containing 4 tablets. The label shows the product is manufactured by Teva Pharmaceuticals USA and distributed by MedVantx, Inc., San Diego, CA. It includes storage instructions to keep at controlled room temperature 20°-25°C and warnings to keep the container tightly closed and out of reach of children. The label also indicates Rx only and that this is a sample not for sale.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
